Leveraging Deep Learning models to identify structurally adequate drug candidates for Parkinson’s Disease
Journal of High School Science · 2024
DOI: 10.64336/001c.120720 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of High School Science, 2024. Verfasst von Raghav Garimella. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Parkinson’s Disease (PD) is a neurodegenerative disease that causes the gradual impairment of movement primarily by mutations in the SNCA (synuclein alpha) gene, excessively producing the alpha-synuclein protein. This protein aggregates in formations known as Lewy Bodies which correlate with neurotransmitter dysfunction, hence leading to the common side-effects of PD, such as loss of balance and memory. Currently, there exist no widely available drugs for PD, partly due to the long process for drugs to be identified, FDA certified, and then marketed. This process, however, can be expedited through the use of drug repurposing by Machine Learning models. The model constructed in this paper utilized the Simplified Molecular Input Line Entry System (SMILES) encoding and vector representations of specific, FDA-approved drugs in order to extract important features of a drug’s molecular structure. Then, disease representation vectors for PD were combined with a drug’s vector representations and were used as inputs to both Deep Learning and Regression models to predict the efficacy of various drug-disease pairs. The use of these models was then applied specifically to PD, identifying the drugs that held promise for therapeutic efficacy in PD. Valproic Acid emerged as a potential drug for further research in its applications to PD, with the best predictive models utilizing Deep Learning. Drugs that are folate or pyridoxine modulators, carbonic anhydrase inhibitors, PPAR-γ modulators, anti-inflammatory agents (prostaglandin modulators, antioxidants, SIRT1 modulators), antifibrinolytics (plasminogen modulators), or those used to treat hyperthyroidism (thyroid hormone inhibitors), were scored high by the model with respect to their ability to modulate brain GABA levels, as were antimetabolites or alkylating agents that modulate nucleotides like adenosine and purine. Deep Learning models with low validation loss can predict drugs that are structurally adequate to provide therapeutic effects for PD and other medicinally under-served diseases.
Zitieren
APA
Garimella, R. (2024). Leveraging Deep Learning models to identify structurally adequate drug candidates for Parkinson’s Disease. Journal of High School Science. https://doi.org/10.64336/001c.120720
Vancouver
Garimella R. Leveraging Deep Learning models to identify structurally adequate drug candidates for Parkinson’s Disease. Journal of High School Science. 2024. doi:10.64336/001c.120720
BibTeX
@article{Garimella2024,
author = {Garimella, Raghav},
title = {Leveraging Deep Learning models to identify structurally adequate drug candidates for Parkinson’s Disease},
journal = {Journal of High School Science},
year = {2024},
doi = {10.64336/001c.120720}
}
EUVIMED